Future studies should also focus on exploring the therapeutic potential of targeting the CYP19A1/estrogen/complex I axis in preclinical models of CRC and evaluating the efficacy of combination therapies involving CYP19A1 inhibitors and conventional chemotherapeutic agents. This evidence concerns the gene CYP19A1 and colorectal carcinoma.